
|Videos|April 27, 2023
ARVO LIVE: OTT166 in the treatment of diabetic retinopathy
Author(s)David Hutton, Martin David Harp
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Advertisement
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
ChatGPT-5 overestimates macular hole surgery success, study finds
5


























